Sow Good Inc. (SOWG): Nasdaq/NYSE listing notice — Sow Good receives Nasdaq bid price deficiency notice; seeks reverse stock split approval

Sow Good Inc.

Received Nasdaq letter May 14, 2025 for failing minimum $1.00 bid price for 30 consecutive business days.
Must regain compliance by Nov 10, 2025; requires closing bid >= $1.00 for 10 consecutive business days.
Annual meeting June 13, 2025 includes proposal to approve 1-for-3 reverse stock split to cure deficiency.
If not compliant by deadline, may seek additional 180-day period or appeal delisting; no assurance of success.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Sow Good Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

May 14, 2025, Sow Good Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”), indicating that, based on the closing bid price for the previous 30 consecutive business days, the listing of the Company's common stock was not in compliance with Nasdaq Listing Rule 5550(a)(2) to maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”). Nasdaq Listing Rule 5810(c)(3)(A) provides a compliance period of 180 calendar days, or until November 10, 2025 (the “Compliance Date”), to regain compliance. If at any time during

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Sow Good Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-074926

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.